Pirfenidone exerts anti-inflammatory effects by inhibiting CXCL6 to alleviate idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) poses a health challenge with the destruction of lung architecture. It is featured by limited effective therapeutic options and a complex pathological mechanism. The molecular mechanism underlying the antifibrotic agent pirfenidone (PFD) remains to be fully determined. This study inv...